Who are Endocyte's investors?

Endocyte's investors include Sanderling Ventures.

Who acquired Endocyte?

Endocyte was acquired by Novartis.

Unicorn exit · $2.1Bacquired by Novartis

1 known investors

Paths you didn't know you had: your email and LinkedIn already hold routes to the Endocyte team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Acquired by Novartis October 2018 · $2.1B ($24 per share, valuing equity at ~$2.1 billion) · source ↗

Novartis is a pharmaceutical company developing breakthrough medicines across therapeutic areas including oncology and cardiovascular disease.

What does Endocyte do?: Novartis is a pharmaceutical company developing breakthrough medicines across therapeutic areas including oncology and cardiovascular disease.
Who are Endocyte's investors?: Endocyte's investors include Sanderling Ventures.
Who acquired Endocyte?: Endocyte was acquired by Novartis.